Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

Table 2 Summary of safety for 5-FU and oxaliplatin-based therapy

Treatment	Author/year	N	Grade 3–4 clinically relevant toxicities > 10% in any trial
Treatment	Author/year	N	Diarrhea	Neutropenia	Anemia	Neurotoxicity	Fatigue^a	Vomiting	Thrombocytopenia
OFF	Pelzer 2009 [28]	37	8.1	NR	NR	10.8	NR	13.5	0
OFF	Pelzer 2011 [27]	23	8.7	NR	NR	NR	NR	NR	NR
OFF	Oettle 2014 [14]	76	1.3	NR	3.9	NR	NR	1.3	1.3
5-FU/OXA-based	Tsavaris 2005 [29]	30	14.2	NR	3.2	4.2	0	0	3.2
FOLFOX	Gebbia 2007 [30]	42	NR	17	14	12	NR	NR	7
FOLFOX	Yoo 2009 [31]	30	0	20	3	0	14	10	3
FOLFOX	Zaanan 2014 [24]	27	0	7.4	7.4	7.4	14.8	0	11.1
FOLFOX	Gill 2016 [16]	49	2	32.7	2	4.1	14.2	4.1	8.2
FOLFOX	Berk 2012 [32]	46	2	22	0	NR	NR	2	7
OFF	El-Hadaad 2013 [33]	30	3.3	23.2	6.6	6.6	NR	3.3	6.6
FOLFOX	Chung 2017 [15]	62	6.5	NR	3.2	0	12.9	4.8	NR
Evaluable patients for each AE, n			410	224	392	307	198	387	367
Weighted average (%)			4.2	21.5	4.5	5.3	11.7	4.1	4.9

Abbreviations: 5-FU 5-fluorouracil, AE adverse event, FOLFOX leucovorin/5-fluorouracil/oxaliplatin, N patients in each study, n evaluable patients for each AE, NR not reported, OFF oxaliplatin/5-fluorouracil/leucovorin, OXA oxaliplatin
^aFatigue includes reported terms of fatigue and asthenia

ISSN: 1471-2407